BYSI - BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia

BeyondSpring ([[BYSI]] +4.3%) presents three abstracts reporting on data from the PROTECTIVE-2 Phase 3 clinical program of plinabulin in combination with pegfilgrastim for prevention of chemotherapy-induced neutropenia ((CIN)) at the 2021 ASCO Annual Meeting held, June 4 - 8.Poster 1: Clinical trial testing superiority of combination plinabulin and pegfilgrastim vs peg alone in patients with breast cancer ((BC)) treated with high febrile neutropenia ((FN)) risk chemotherapy: The FN incidence (3.6%) in the combination arm is ~50% of that of the pegfilgrastim arm (6.3%), and has 50% shorter duration of FN (1.25 day vs. 2.28 day);Duration of hospitalization is ~50% less in the combination arm (3.75 day) compared to that in pegfilgrastim arm (7.14 day);The clinical consequence of changing chemo dose and/or chemo regimen in later cycles is ~50% lower in the combination vs. pegfilgrastim alone (2.7% vs. 6.3%).Poster 2: Chemotherapy induced profound neutropenia ((PN)) in BC patients after chemotherapy and

For further details see:

BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia